Pharming (PHAR) Assets Average (2021 - 2026)
Pharming's (PHAR) quarterly Assets Average came in at $478.7 million in Q2 2026, up 12.7% YoY from $424.7 million in Q2 2025, and down 3.23% on a QoQ basis from $494.7 million in Q1 2026.
Pharming (PHAR) Assets Average (2021 - 2026) Analysis & Trends
Pharming (PHAR) has 6 years of Assets Average data on file, last reported at $478.7 million in Q2 2026.
- Quarterly Assets Average rose 12.7% year-over-year to $478.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $478.7 million (up 12.7% YoY) and the FY2025 annual result came in at $450.0 million, up 4.3% from the prior year.
- Assets Average eased to $478.7 million in Q2 2026, from $494.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $191.4 billion in Q4 2022 to a low of $196.6 million in Q1 2022.
- A 5-year average of $21.6 billion and a median of $431.0 million in 2023 frame the typical range for Assets Average.
- The widest YoY moves for Assets Average: up 95267.47% in 2022, down 99.91% in 2022.
- Tracing PHAR's Assets Average over 5 years: stood at $191.4 billion in 2022, then tumbled by 99.77% to $449.7 million in 2023, then fell by 8.21% to $412.7 million in 2024, then rose by 17.96% to $486.9 million in 2025, then slipped by 1.68% to $478.7 million in 2026.
- The last three Assets Average figures came in at $478.7 million (Q2 2026), $494.7 million (Q1 2026), and $486.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | 478.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 478.67 Mn |
| Mar 31, 2026 | 494.66 Mn |
| Dec 31, 2025 | 486.87 Mn |
| Sep 30, 2025 | 460.02 Mn |
| Jun 30, 2025 | 424.72 Mn |
| Mar 31, 2025 | 401.58 Mn |
| Dec 31, 2024 | 412.75 Mn |
| Sep 30, 2024 | 420.72 Mn |
| Jun 30, 2024 | 428.80 Mn |
| Mar 31, 2024 | 452.26 Mn |
| Dec 31, 2023 | 449.66 Mn |
| Sep 30, 2023 | 433.14 Mn |
| Jun 30, 2023 | 426.40 Mn |
| Mar 31, 2023 | 424.40 Mn |
| Dec 31, 2022 | 191.37 Bn |
| Sep 30, 2022 | 191.36 Bn |
| Jun 30, 2022 | 393.35 Mn |
| Mar 31, 2022 | 196.60 Mn |
| Dec 31, 2021 | 200.67 Mn |
| Sep 30, 2021 | 406.39 Mn |